Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...

Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

JPMorgan says Astellas Pharma’s (ALPMY) (ALMPY) announcement that the FDA has issued a Complete Response Letter regarding for Izervay in ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Izervay (avacincaptad pegol) has been cleared by the US regulator for GA secondary to age-related macular degeneration (AMD), a leading form of blindness, setting up a market clash with Apellis ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

These injections deliver medication such as the new geographic atrophy drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), powerful anti-VEGFs (vascular endothelial growth factor) to keep ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

In August 2023, the FDA approved Izervay to treat the same patient population. Japan's Astellas Pharma (OTC: ALPMY) invested $5.9 billion to acquire the company that developed Izervay. Competing ...

Sales of Strategic Brands supporting our future growth namely PADCEV, IZERVAY, VEOZAH, VYLOY, and XOSPATA expanded to over 150 billion yen in total with a robust growth of additional 90 billion ...